Sabby Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sabby Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-486	Closed	-$7.28M	–	182
2017 Q4	$7.28M	Sell	486 -771	-61%	-$114K	0.66%	29
2017 Q3	$19.1M	Buy	1,257 +446	+55%	+$67.1K	1.25%	16
2017 Q2	$10.5M	Buy	811 +269	+50%	+$32.4K	0.68%	23
2017 Q1	$5.93M	Buy	542 +246	+83%	+$21.7K	0.32%	43
2016 Q4	$2.18M	Buy	296 +36	+14%	+$2.93K	0.13%	95
2016 Q3	$2.27M	Hold	260	–	–	0.08%	119
2016 Q2	$2.24M	Buy	260 +227	+688%	+$19.6K	0.12%	102
2016 Q1	$262K	Buy	+33	New	+$2.98K	0.01%	247
2015 Q1	–	Sell	-9,592	Closed	-$114M	–	326
2014 Q4	$114M	Hold	9,592	–	–	3.6%	7
2014 Q3	$108M	Sell	9,592 -374	-4%	-$35.6K	4.14%	6
2014 Q2	$94.4M	Buy	9,966 +4,040	+68%	+$283K	4.05%	4
2014 Q1	$41.9M	Sell	5,926 -3,842	-39%	-$304K	2.35%	9
2013 Q4	$72.6M	Buy	9,768 +3,217	+49%	+$224K	4.63%	4
2013 Q3	$49.7M	Buy	6,551 +1,294	+25%	+$103K	3.23%	8
2013 Q2	$42M	Buy	+5,257	New	+$387K	2.8%	9

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sabby Management's VRTX Position: Q2 2016 in Review

Sabby Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 23,320 shares — an estimated $2.02M sold.

Sabby Management first reported a position in VRTX in Q2 2013 and held it in 5 quarters. The position peaked at $25.5M in Q3 2013. 483 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

Sabby Management reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Sabby Management sold 23,320 Vertex Pharmaceuticals shares in Q2 2016, an estimated $2.02M.
Sabby Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Sabby Management's Vertex Pharmaceuticals position peaked at $25.5M in Q3 2013.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.